Steinberg Asset Management Upped Lkq (LKQ) Holding; Blueprint Medicines (BPMC) Had 10 Analysts Last Week

December 6, 2017 - By Adrian Mccoy

Among 10 analysts covering Blueprint Medicine Corp (NASDAQ:BPMC), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Blueprint Medicine Corp had 20 analyst reports since February 22, 2016 according to SRatingsIntel. The rating was maintained by Canaccord Genuity on Wednesday, September 20 with “Buy”. The stock of Blueprint Medicines Corporation (NASDAQ:BPMC) has “Buy” rating given on Monday, March 13 by Goldman Sachs. The stock of Blueprint Medicines Corporation (NASDAQ:BPMC) has “Buy” rating given on Monday, November 13 by BTIG Research. The stock of Blueprint Medicines Corporation (NASDAQ:BPMC) earned “Buy” rating by Cowen & Co on Wednesday, August 2. Jefferies maintained Blueprint Medicines Corporation (NASDAQ:BPMC) on Tuesday, June 6 with “Buy” rating. The rating was initiated by Raymond James on Friday, May 27 with “Outperform”. Canaccord Genuity initiated Blueprint Medicines Corporation (NASDAQ:BPMC) on Friday, August 5 with “Buy” rating. The firm has “Buy” rating by BTIG Research given on Friday, September 29. Canaccord Genuity maintained Blueprint Medicines Corporation (NASDAQ:BPMC) on Wednesday, August 2 with “Buy” rating. The firm earned “Buy” rating on Wednesday, November 1 by Canaccord Genuity. See Blueprint Medicines Corporation (NASDAQ:BPMC) latest ratings:

13/11/2017 Broker: BTIG Research Rating: Buy New Target: $90.0 Maintain
06/11/2017 Broker: Wedbush Rating: Buy New Target: $82.0 Maintain
01/11/2017 Broker: Canaccord Genuity Rating: Buy New Target: $80.0 Maintain
31/10/2017 Broker: BTIG Research Rating: Buy New Target: $90.0 Maintain
23/10/2017 Broker: Morgan Stanley Rating: Overweight Old Target: $45 New Target: $78 Maintain
10/10/2017 Broker: Jefferies Rating: Buy New Target: $56.0 Maintain
29/09/2017 Broker: BTIG Research Rating: Buy New Target: $90.0 Initiate
29/09/2017 Broker: DA Davidson Rating: Buy New Target: $90 Initiates Coverage On
20/09/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $56 New Target: $66 Maintain
04/09/2017 Broker: Jefferies Rating: Buy New Target: $56.0 Maintain

Steinberg Asset Management Llc increased Lkq Corp (LKQ) stake by 97.54% reported in 2017Q2 SEC filing. Steinberg Asset Management Llc acquired 82,130 shares as Lkq Corp (LKQ)’s stock declined 2.79%. The Steinberg Asset Management Llc holds 166,330 shares with $5.48M value, up from 84,200 last quarter. Lkq Corp now has $12.14B valuation. The stock increased 0.08% or $0.03 during the last trading session, reaching $39.27. About 378,205 shares traded. LKQ Corporation (NASDAQ:LKQ) has declined 1.30% since December 6, 2016 and is downtrending. It has underperformed by 18.00% the S&P500.

The stock decreased 4.47% or $3 during the last trading session, reaching $64.09. About 280,724 shares traded. Blueprint Medicines Corporation (NASDAQ:BPMC) has risen 128.96% since December 6, 2016 and is uptrending. It has outperformed by 112.26% the S&P500.

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. The company has market cap of $2.51 billion. The Company’s lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It currently has negative earnings. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase and predicted NTRK resistant mutants.

Among 9 analysts covering LKQ (NASDAQ:LKQ), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. LKQ had 18 analyst reports since January 15, 2016 according to SRatingsIntel. Jefferies initiated it with “Buy” rating and $37.0 target in Friday, January 15 report. Sterne Agee CRT initiated the stock with “Buy” rating in Wednesday, March 2 report. Jefferies initiated the shares of LKQ in report on Monday, January 18 with “Buy” rating. Stifel Nicolaus reinitiated the stock with “Buy” rating in Tuesday, November 29 report. The company was maintained on Wednesday, August 30 by Robert W. Baird. Robert W. Baird maintained LKQ Corporation (NASDAQ:LKQ) rating on Tuesday, March 22. Robert W. Baird has “Outperform” rating and $36 target. The rating was maintained by Robert W. Baird on Thursday, October 26 with “Buy”. The firm has “Neutral” rating by Northcoast given on Tuesday, July 25. The rating was initiated by JP Morgan on Tuesday, February 21 with “Overweight”. The firm has “Buy” rating by Stifel Nicolaus given on Monday, September 25.

Steinberg Asset Management Llc decreased Willis Towers Watson Pub Ltd stake by 12,040 shares to 35,564 valued at $5.17 million in 2017Q2. It also reduced Charter Communications Inc N stake by 6,694 shares and now owns 17,244 shares. Madison Square Garden Co New was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com